100,000 Shares in Urogen Pharma $URGN Bought by Elmind Capital LP

Elmind Capital LP acquired a new position in shares of Urogen Pharma (NASDAQ:URGN) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 100,000 shares of the company’s stock, valued at approximately $2,342,000. Urogen Pharma comprises approximately 0.7% of Elmind Capital LP’s holdings, making the stock its 26th biggest position. Elmind Capital LP owned 0.21% of Urogen Pharma at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Cinctive Capital Management LP bought a new stake in shares of Urogen Pharma during the 4th quarter worth $398,000. MPM Bioimpact LLC lifted its position in shares of Urogen Pharma by 597.3% during the 4th quarter. MPM Bioimpact LLC now owns 941,378 shares of the company’s stock worth $22,047,000 after buying an additional 806,378 shares during the last quarter. Paradigm Biocapital Advisors LP lifted its position in shares of Urogen Pharma by 6.1% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,473,648 shares of the company’s stock worth $104,773,000 after buying an additional 257,564 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Urogen Pharma by 72.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 616,606 shares of the company’s stock worth $14,441,000 after buying an additional 259,991 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its position in shares of Urogen Pharma by 1,323.0% during the 4th quarter. Russell Investments Group Ltd. now owns 47,257 shares of the company’s stock worth $1,107,000 after buying an additional 43,936 shares during the last quarter. 91.29% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Urogen Pharma

In other news, insider Mark Schoenberg sold 5,222 shares of the stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $27.30, for a total value of $142,560.60. Following the completion of the sale, the insider owned 139,763 shares of the company’s stock, valued at approximately $3,815,529.90. This represents a 3.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 4.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on URGN shares. Oppenheimer reiterated an “outperform” rating on shares of Urogen Pharma in a research report on Tuesday, June 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Monday, April 20th. HC Wainwright reiterated a “buy” rating and issued a $45.00 target price on shares of Urogen Pharma in a research report on Wednesday, June 3rd. D. Boral Capital reiterated a “buy” rating and issued a $33.00 target price on shares of Urogen Pharma in a research report on Tuesday, March 31st. Finally, LADENBURG THALM/SH SH started coverage on Urogen Pharma in a research report on Monday, May 11th. They issued a “buy” rating and a $43.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $39.50.

Urogen Pharma Trading Up 2.7%

Urogen Pharma stock opened at $32.81 on Thursday. The company has a market capitalization of $1.60 billion, a PE ratio of -11.93 and a beta of 1.59. Urogen Pharma has a 12 month low of $12.73 and a 12 month high of $33.40. The stock has a 50-day moving average price of $26.51 and a two-hundred day moving average price of $22.90.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.01. The company had revenue of $50.96 million during the quarter, compared to analyst estimates of $44.83 million. As a group, analysts predict that Urogen Pharma will post -0.98 earnings per share for the current fiscal year.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.